- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise
June 10th 2024, 8:00pm
A novel radioligand therapy, JNJ-6420, demonstrates potential in treating mCRPCr, delivering sustained responses following only 1-2 doses.
ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC
June 10th 2024, 1:43pm
The investigational PROTAC AR degrader ARV-766 showed promising clinical activity and tolerability in patients with metastatic castration-resistant prostate cancer.
MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer
June 8th 2024, 10:00am
MammaPrint high 2 HR-positive/HER2-negative early-stage breast cancer exhibited a heightened immune active state.
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma
June 7th 2024, 8:15pm
Linvoseltamab elicited outcomes equivalent to those seen with teclistamab in patients with triple-class exposed relapsed/refractory multiple myeloma.
Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer
June 7th 2024, 7:00pm
Dostarlimab plus carboplatin and paclitaxel improved PFS and OS in dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC
June 7th 2024, 6:00pm
Pembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.
Dr Hughes on Efficacy Data for Asciminib in Newly Diagnosed Ph+ CP-CML
June 7th 2024, 5:00pm
Timothy Hughes, MD, MBBS, FRACP, FRCPA discussed findings from the ASC4FIRST trial comparing asciminib vs investigator-selected TKIs in CP-CML.
Nivolumab/Cabozantinib Combination Prolongs Treatment-Free Survival in Advanced RCC
June 6th 2024, 5:00pm
Partition overall survival data indicated that nivolumab plus cabozantinib extended treatment-free survival vs sunitinib in advanced renal cell carcinoma.
High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab
June 6th 2024, 3:13pm
Cretostimogene grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC according to the phase 2 CORE-001 trial.
Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer
June 6th 2024, 2:29pm
Apalutamide/ADT maintains quality of life, demonstrates improved PSA progression-free survival in recurrent prostate cancer according to PRESTO trial.
Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer
June 5th 2024, 8:00pm
Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.
Daratumumab Retreatment Leads to Responses in Relapsed/Refractory Myeloma
June 5th 2024, 7:00pm
Retreatment with daratumumab-based regimens led to a similar ORR vs initial daratumumab treatment in relapsed/refractory myeloma.
Enzalutamide Treatment Suspension Has No Significant Impact on QOL in nmHSPC
June 5th 2024, 6:00pm
Treatment cessation of enzalutamide-containing regimens in responding patients had no impact on QOL in biochemically recurrent nmHSPC.
Updated Analysis From MajesTEC-1 Confirms CRS Reduction With Prophylactic Tocilizumab in Relapsed/Refractory Myeloma
June 5th 2024, 2:42pm
Updated Analysis from Phase 1/2 MajesTEC-1 trial support the use of prophylactic tocilizumab to reduce the risk of cytokine release syndrome associated with outpatient administration of teclistamab.
Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer
June 5th 2024, 1:27pm
Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.
Olverembatinib Demonstrates Early Activity, Tolerability in SDH-deficient GIST
June 4th 2024, 9:24pm
Olverembatinib showed antitumor activity in patients with TKI-resistant, SDH-deficient GISTs and paraganglioma.
TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases
June 4th 2024, 7:19pm
TTFields therapy plus best supportive care increased time to first intracranial progression by 10.6 months in patients with NSCLC brain metastases.
Dr Eads on Nivolumab Plus Neoadjuvant Chemoradiation in Esophageal/GEJ Cancer
June 4th 2024, 7:15pm
Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.
Dr Classe on Lymphadenectomy Omission in Advanced Epithelial Ovarian Cancer
June 4th 2024, 6:55pm
Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.
Frontline Petosemtamab Doublet Elicits Responses in Recurrent/Metastatic HNSCC
June 4th 2024, 6:20pm
Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma